These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 19522503

  • 21. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AH.
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [Abstract] [Full Text] [Related]

  • 22. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor.
    Shin HC, Song DW, Baek WK, Lee SR, Kwon TK, Lee J, Park SH, Jang BC, Park JW.
    Chemotherapy; 2009; 55(5):353-62. PubMed ID: 19657189
    [Abstract] [Full Text] [Related]

  • 23. New targets in oncology drug development.
    Verweij J.
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):754-5. PubMed ID: 16258482
    [No Abstract] [Full Text] [Related]

  • 24. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C.
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [Abstract] [Full Text] [Related]

  • 25. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 26. Epigenetic deregulation of DNA repair and its potential for therapy.
    Hegi ME, Sciuscio D, Murat A, Levivier M, Stupp R.
    Clin Cancer Res; 2009 Aug 15; 15(16):5026-31. PubMed ID: 19671858
    [Abstract] [Full Text] [Related]

  • 27. Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.
    Zhu Y, Hu J, Hu Y, Liu W.
    Cancer Treat Rev; 2009 Nov 15; 35(7):590-6. PubMed ID: 19635647
    [Abstract] [Full Text] [Related]

  • 28. [Cell cycle and effect of antineoplastic agents].
    Niitani H, Shibuya M.
    Kokyu To Junkan; 1984 Dec 15; 32(12):1245-50. PubMed ID: 6396783
    [No Abstract] [Full Text] [Related]

  • 29. Anticancer activity and mechanisms of diacetyldianhydrogalactitol on hepatoma QGY-7703 cells.
    Zhang XY, Lian Yan X, Guo W, Xu B, Li M, Zhou Y, Rong Cui J.
    Anticancer Drugs; 2009 Nov 15; 20(10):926-31. PubMed ID: 19741503
    [Abstract] [Full Text] [Related]

  • 30. [Cell cycle and checkpoints in oncology: new therapeutic targets].
    Pommier Y, Kohn KW.
    Med Sci (Paris); 2003 Feb 15; 19(2):173-86. PubMed ID: 12836612
    [Abstract] [Full Text] [Related]

  • 31. [Current aspects of drug therapy of cancer].
    Vicente J.
    Rev Clin Esp; 1970 Dec 31; 119(6):501-16. PubMed ID: 4928318
    [No Abstract] [Full Text] [Related]

  • 32. Drug-DNA interactions: new discoveries and possibilities for cancer treatment.
    Souhami RL.
    Q J Med; 1994 Apr 31; 87(4):195-7. PubMed ID: 8208908
    [No Abstract] [Full Text] [Related]

  • 33. Artificial signal transduction therapy: a futuristic approach to disease treatment.
    Peri-Naor R, Motiei L, Margulies D.
    Future Med Chem; 2015 Apr 31; 7(16):2091-3. PubMed ID: 26510968
    [No Abstract] [Full Text] [Related]

  • 34. The effect of MAPK inhibitors on arsenic trioxide-treated Calu-6 lung cells in relation to cell death, ROS and GSH levels.
    Han YH, Moon HJ, You BR, Kim SZ, Kim SH, Park WH.
    Anticancer Res; 2009 Oct 31; 29(10):3837-44. PubMed ID: 19846917
    [Abstract] [Full Text] [Related]

  • 35. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades.
    Bidwell GL, Raucher D.
    Expert Opin Drug Deliv; 2009 Oct 31; 6(10):1033-47. PubMed ID: 19637980
    [Abstract] [Full Text] [Related]

  • 36. Design of new anticancer therapies targeting cell cycle checkpoint pathways.
    Sampath D, Plunkett W.
    Curr Opin Oncol; 2001 Nov 31; 13(6):484-90. PubMed ID: 11673689
    [Abstract] [Full Text] [Related]

  • 37. Selective antagonism of anticancer drugs for side-effect removal.
    Fernández A, Sessel S.
    Trends Pharmacol Sci; 2009 Aug 31; 30(8):403-10. PubMed ID: 19595465
    [Abstract] [Full Text] [Related]

  • 38. [The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line].
    Xia JS, Chen XG, Zhuang QY, Liu JH, Ye ZQ.
    Zhonghua Nan Ke Xue; 2009 Jul 31; 15(7):617-20. PubMed ID: 19694375
    [Abstract] [Full Text] [Related]

  • 39. Introduction: targeting different pathways to prevent tumor cell development.
    Kantarjian HM.
    Semin Oncol; 2009 Apr 31; 36(2 Suppl 1):S1-5. PubMed ID: 19393830
    [No Abstract] [Full Text] [Related]

  • 40. [Molecular mechanism of cell death induced by chemotherapeutic agents].
    Saya H.
    Brain Nerve; 2009 Jul 31; 61(7):843-7. PubMed ID: 19618862
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.